This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, J.-w. Articles by Dang, C. V. Search for Related Content PubMed PubMed Citation Articles by Kim, J.-w. Articles by Dang, C. V. Related Collections Cellular Pathobiology Cellular Pathobiology: Metabolism and Physiology

Cancer's Molecular Sweet Tooth and the Warburg Effect

¹ Division of Hematology, Department of Medicine, ² The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: Chi V. Dang, Ross Research Building, Room 1032, 720 Rutland Avenue, Baltimore, MD 21205. Phone: 410-955-2773; Fax: 410-955-0185; E-mail: cvdang{at}jhmi.edu.

	Abstract

Top Abstract Introduction Oncogenes, Tumor Suppressors,... Oncogenic Activation of HIF... PDK1 and Aerobic Glycolysis Does Aerobic Glycolysis... References

 
More than 80 years ago, the renowned biochemist Otto Warburg described how cancer cells avidly consume glucose and produce lactic acid under aerobic conditions. Recent studies arguing that cancer cells benefit from this phenomenon, termed the Warburg effect, have renewed discussions about its exact role as cause, correlate, or facilitator of cancer. Molecular advances in this area may reveal tactics to exploit the cancer cell's "sweet tooth" for cancer therapy. (Cancer Res 2006; 66(18): 8927-30)

	Introduction

Top Abstract Introduction Oncogenes, Tumor Suppressors,... Oncogenic Activation of HIF... PDK1 and Aerobic Glycolysis Does Aerobic Glycolysis... References

 
ATP required for normal cell proliferation and survival comes primarily from two sources. The first is glycolysis, which comprises a series of reactions that metabolizes glucose to pyruvate in the cytoplasm to produce a net of 2 ATP from each glucose. The other is the tricarboxylic acid (TCA) or Krebs cycle, which uses pyruvate formed from glycolysis in a series of reactions that donate electrons via NADH and FADH₂ to the respiratory chain complexes in mitochondria. With oxygen serving as the final electron acceptor, electron transfer creates across the mitochondrial inner membrane, a proton gradient of which the dissipation through ATP synthase forms 36 ATP per glucose molecule. With limited oxygen, such as with muscles that have undergone prolonged exercise, pyruvate is not used in the TCA cycle and is converted into lactic acid by lactate dehydrogenase (LDH) in a process termed anaerobic glycolysis (Fig. 1 ).

View larger version (46K): [in this window] [in a new window]   Figure 1. Molecular underpinnings of the Warburg effect. The Warburg effect (highlighted) describes the enhanced conversion of glucose to lactate by tumor cells, even in the presence of adequate oxygen that would ordinarily be used for oxidative phosphorylation. Activation of the AKT oncogene results in increased glucose transportation and stimulation of HK2 activity, which enhances glycolytic rates. The MYC oncogene is depicted to activate glycolytic genes and mitochondrial biogenesis, which when sustained by high MYC levels can result in reactive oxygen species (ROS) production. ROS could, in turn, cause mtDNA mutations that render mitochondria dysfunctional. p53 is shown to stimulate respiration through activation of a component of the respiratory chain. In addition to hypoxic stabilization, HIF-1 is shown to be increased by RAS and loss of VHL, which mediates its degradation. HIF-1 transactivates glycolytic genes as well as directly activates the PDK1 gene, which in turn inhibits PDH that catalyzes the conversion of pyruvate to acetyl-CoA. Acetyl-CoA is shown to enter the TCA cycle, which donates electrons to the mitochondrial respiratory chain complexes I to IV. Inhibition of PDH by PDK1 attenuates mitochondrial function, resulting in the shunting of pyruvate to lactate.

	Oncogenes, Tumor Suppressors, and the Warburg Effect

Top Abstract Introduction Oncogenes, Tumor Suppressors,... Oncogenic Activation of HIF... PDK1 and Aerobic Glycolysis Does Aerobic Glycolysis... References

 
To account for the conversion of glucose to lactate by cancer cells in the presence of oxygen, Warburg (1) speculated that tumor mitochondria are decreased or functionally impaired. In fact, Warburg suggested that impaired mitochondrial function contributes to tumorigenesis. Recent studies suggest that mutations affecting mitochondrial DNA (mtDNA) or enzymes of the TCA cycle might contribute to the Warburg effect. Mutations of mtDNA, which are prevalent in human cancers, could render the mtDNA encoded components of the respiratory chain complexes defective. Intriguingly, the subunits of the TCA cycle enzyme SDH (SDHB, SDHC, and SDHD) behave as classic tumor suppressors in pheochromocytoma or paraganglioma (2). Furthermore, FH is a tumor suppressor in leiomyoma and renal cell carcinoma. Although these observations suggest that mitochondrial function may be compromised by mutations in mitochondrial enzymes, there is no direct evidence that these mutations are sufficient for tumorigenesis. In this regard, there is no evidence that respiration is, in fact, less active in cancer cells than in normal cells. Hence, further studies are required to address whether impaired mitochondrial function sufficiently contributes to tumorigenesis.

Several oncogenes have been implicated in the Warburg effect. The AKT oncogene, which encodes a protein serine-threonine kinase, is associated with enhanced glucose uptake and aerobic glycolysis seemingly independent of HIF-1 (3). AKT mobilizes glucose transporters to the cell surface to enhance glucose uptake and activates hexokinase 2 (HK2) to phosphorylate and trap intracellular glucose. Through these effects, AKT is able to enhance glycolytic flux without affecting mitochondrial oxidative phosphorylation, thereby presumably contributing to the Warburg effect. The MYC oncogene, which is widely activated in human cancers, has also been implicated in the direct activation of aerobic glycolysis. The Myc transcription factor activates virtually all glycolytic enzyme genes and directly binds numerous glycolytic genes, including those encoding HK2, enolase, and LDHA (4). In immortalized rat fibroblasts, Myc is able to enhance aerobic glycolysis; however, activation of MYC in a human B cell model resulted in increased respiration that was associated with increased mitochondrial biogenesis (5). Elevated and sustained activation of MYC, however, is tightly associated with increased mitochondrial reactive oxygen species, which may cause mtDNA mutations that in turn contribute to dysfunctional mitochondria (6). Intriguingly, the tumor suppressor p53, which is frequently mutated in human cancers, also stimulates mitochondrial respiration by directly transactivating the SCO2 gene for synthesis of cytochrome c oxidase 2 (7). SCO2 is required for the assembly of the COXII (MTCO2) subunit into the cytochrome c oxidase complex, which is integral to the respiratory chain. Loss of either p53 or SCO2 expression results in a switch from cellular respiration to aerobic glycolysis, suggesting that inactivation of p53 in human cancers may directly contribute to the Warburg effect. In aggregate, these observations suggest that oncogenes or tumor suppressors could independently or cooperatively contribute to the Warburg effect.

Tumor progression, as modeled by serial transduction of normal human cells with immortalizing and oncogenic events, is associated with the emergence of the Warburg effect (8). Through comprehensive multidimensional metabolic profiling of stepwise transformed primary human cells, highly tumorigenic cells transformed by hTERT, large T antigen, small T antigen, and oncogenic H-Ras were found to have high rates of lactate production with low mitochondrial mass. In contrast, cells lacking H-Ras but transformed by the other three genes had high mitochondrial mass and a high oxygen consumption rate with lower lactate production. These results provide evidence that serial oncogenic activation transforms metabolism toward aerobic glycolysis.

	Oncogenic Activation of HIF and Aerobic Glycolysis

Top Abstract Introduction Oncogenes, Tumor Suppressors,... Oncogenic Activation of HIF... PDK1 and Aerobic Glycolysis Does Aerobic Glycolysis... References

 
In addition to oncogenic activation of aerobic glycolysis, the activation of HIF, a transcription factor that is stabilized in response to hypoxia, also significantly contributes to the conversion of glucose to lactate. HIF-1 consists of an oxygen sensitive HIF-1 subunit that heterodimerizes with HIF-1ß to bind DNA. In high oxygen tension, HIF-1 is hydroxylated by prolyl hydroxylases (PHD) using -ketoglutarate derived from the TCA cycle. The hydroxylated HIF-1 subunit is recognized by the von Hippel Lindau (VHL) protein and destined for degradation by proteasomes, such that HIF-1 is continuously synthesized and degraded under nonhypoxic conditions. Hypoxia is a pathophysiologic stimulus of anaerobic glycolysis through stabilization of HIF-1 and its direct transactivation of glycolytic enzyme genes. Hence, adaptation to the hypoxic tumor microenvironment results in increased glucose uptake and lactate production.

In addition to hypoxia, oncogenic events have been linked to stabilization of HIF in the presence of adequate oxygen. Activation of the Src oncogene increased in vivo tumorigenecity as well as HIF-1 levels in nonhypoxic conditions (9). Oncogenic H-Ras has been reported to increase the level of HIF-1 (10), and phosphatidylinositol 3-kinase signaling may stabilize HIF-1 (9). In renal cell carcinoma, mutations in the VHL tumor suppressor disrupt its function, which is necessary for the oxygen-dependent prolyl hydroxylation and proteasomal degradation of HIF-1 (11). Moreover, mutations of the TCA cycle tumor suppressors, SDH and FH, have also been linked to the stabilization of HIF. In particular, prolyl hydroxylation of HIF-1 requires -ketoglutarate as a substrate, which is converted to succinate, such that deficiency of SDH or FH decreases -ketoglutarate or increases succinate, thereby inhibiting the degradation of HIF-1 (12). Taken together, activation of certain oncogenic pathways stabilizes HIF-1 protein under nonhypoxic conditions, resulting in activation of glycolytic metabolism. However, activation of glycolytic flux alone would not account for the Warburg effect, which is also associated with diminished mitochondrial function that has been thought to decrease passively due to the lack of oxygen.

	PDK1 and Aerobic Glycolysis

Top Abstract Introduction Oncogenes, Tumor Suppressors,... Oncogenic Activation of HIF... PDK1 and Aerobic Glycolysis Does Aerobic Glycolysis... References

 
Two recent studies provide insight into the Warburg effect via a novel HIF-1-mediated mechanism that actively inhibits mitochondrial function (13, 14). PDK1, which is one of four family members, was identified as a direct HIF-1 target gene in hypoxic cells. PDK1 phosphorylates and inactivates the mitochondrial pyruvate dehydrogenase (PDH) complex. Suppression of PDH by PDK1 inhibits the conversion of pyruvate to acetyl-CoA, thereby attenuating mitochondrial function and respiration (Fig. 1). Because nonhypoxic stabilization of HIF through oncogenic events has been observed in many types of tumors, we hypothesize that PDK1 levels may be up-regulated in nonhypoxic tumor cells by HIF, which would divert pyruvate from PDH and result in the increased lactate production (Fig. 1). A recent immunohistochemical study further provided evidence that PDK1 expression is elevated in non–small-cell lung cancers (15). Intriguingly, PDH expression seems to be reduced in high PDK1-expressing cancer cells. These studies suggest that PDK1 activation may be a key regulatory switch contributing to the Warburg effect. In aggregate, the activation of oncogenes, such as AKT, MYC, and RAS, along with the stabilization of HIF can enhance aerobic glycolysis or the Warburg effect through increased glycolytic flux and attenuation of mitochondrial function.

	Does Aerobic Glycolysis Participate in Tumorigenesis?

Top Abstract Introduction Oncogenes, Tumor Suppressors,... Oncogenic Activation of HIF... PDK1 and Aerobic Glycolysis Does Aerobic Glycolysis... References

 
Aerobic glycolysis may provide cancer cells growth advantage in the tumor microenvironment (16). Although ATP production through the glycolytic pathway is much less efficient stoichiometrically as compared with mitochondrial oxidative phosphorylation, activation of AKT could provide cells with sufficiently high glycolytic fluxes to maintain a higher than adequate level of ATP (17). In fact, excess pyruvate in cells with a high rate of glucose utilization is redirected toward lipid synthesis through ATP citrate lyase (18). As such, activation of aerobic glycolysis liberates cancer cells from oxygen dependency for ATP production, particularly in the hypoxic tumor microenvironment. This liberation, however, could be exploited for therapeutic purposes. For example, inhibition of ATP citrate lyase can suppress tumor cell growth (18). Inhibition of glycolysis can overcome tumor drug resistance (19). Furthermore, inhibition of HIF-1 or PDK1, which causes further mitochondrial oxygen depletion, renders cells more susceptible to anoxia-induced cell death or sensitivity to tirapazamine, a chemotherapeutic agent that is activated by the absence of oxygen (13).

Aerobic glycolysis may also participate in tumorigenesis, which is characterized by cellular immortalization and subsequent malignant transformation. Recent evidence suggests that increased aerobic glycolysis could contribute to immortalization of cells. A recent expression cloning study identified two glycolytic genes, encoding glucose phosphate isomerase and phosphoglycerate mutase, capable of immortalizing primary human cells, increasing glycolysis, and attenuating mitochondrial generation of reactive oxygen species that are known to cause cellular senescence (20). The loss of classic tumor suppressor genes encoding enzymes of the TCA cycle also suggests that aerobic glycolysis may significantly contribute to tumorigenesis; however, it should be noted that the stabilization of HIF-1 in these tumors may convey other advantages such as the induction of angiogenesis. In this regard, the Warburg effect could be considered as a positive modifier of cancer, such that it may not be causative but rather facilitates tumor progression.

In addition to metabolic advantages of increased aerobic glycolysis, the nonglycolytic functions of glycolytic enzymes may also contribute to tumorigenesis through the antiapoptotic effects of HK2, cell cycle–dependent transcriptional regulation by LDH and glyceraldehyde 3-phosphate dehydrogenase, and enhanced cell motility by glucose phosphate isomerase (autocrine motility factor; ref. 4). Taken together, the switch to glycolytic metabolism may contribute to tumor development through enhanced glycolytic flux and/or the multifaceted functions of glycolytic enzymes. It should be noted, however, that the role of normal mitochondrial function in tumorigenesis is not well defined, and hence the recent findings on cancer's molecular sweet tooth should not dissuade from the strife for a deeper understanding of mitochondrial function in cancer glucose metabolism.

	Acknowledgments

 
Grant support: NIH grants CA51497, CA57341, and NHLBI NO1-HV-28180.

We thank Drs. Lawrence Gardner, Feng Li, and Karen Zeller for comments.

	Footnotes

 
Note: C.V. Dang is the Hopkins Family Professor in Oncology Research and J.W. Kim is a Howard Hughes Medical Institute Predoctoral Fellow.

Received 4/24/06. Revised 6/ 8/06. Accepted 6/23/06.

	References

Top Abstract Introduction Oncogenes, Tumor Suppressors,... Oncogenic Activation of HIF... PDK1 and Aerobic Glycolysis Does Aerobic Glycolysis... References

 

1. Warburg O. On the origin of cancer cells. Science 1956;123:309–14.[Free Full Text]
2. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005;5:857–66.[CrossRef][Medline]
3. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004;64:3892–9.[Abstract/Free Full Text]
4. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005;30:142–50.[CrossRef][Medline]
5. Li F, Wang Y, Zeller KI, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 2005;25:6225–34.[Abstract/Free Full Text]
6. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2004;2:203–14.[Abstract/Free Full Text]
7. Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science 2006;312:1650–3.[Abstract/Free Full Text]
8. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A 2005;102:5992–7.[Abstract/Free Full Text]
9. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–32.[CrossRef][Medline]
10. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001;276:9519–25.[Abstract/Free Full Text]
11. Kaelin WG, Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673–82.[CrossRef][Medline]
12. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF- prolyl hydroxylase. Cancer Cell 2005;7:77–85.[CrossRef][Medline]
13. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively down-regulating mitochondrial oxygen consumption. Cell Metab 2006;3:187–97.[CrossRef][Medline]
14. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177–85.[CrossRef][Medline]
15. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia 2005;7:1–6.[CrossRef][Medline]
16. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891–9.[CrossRef][Medline]
17. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005;24:7435–42.[CrossRef][Medline]
18. Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005;8:311–21.[CrossRef][Medline]
19. Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613–21.[Abstract/Free Full Text]
20. Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005;65:177–85.[Abstract/Free Full Text]

This article has been cited by other articles:

				H. Nam, B. C. Chung, Y. Kim, K. Lee, and D. Lee Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification Bioinformatics, December 1, 2009; 25(23): 3151 - 3157. [Abstract] [Full Text] [PDF]

				C. V. Dang PKM2 Tyrosine Phosphorylation and Glutamine Metabolism Signal a Different View of the Warburg Effect Sci. Signal., November 17, 2009; 2(97): pe75 - pe75. [Abstract] [Full Text] [PDF]

				J. S. Brockenbrough, J. K. Morihara, S. E. Hawes, J. E. Stern, J. S. Rasey, L. W. Wiens, Q. Feng, and H. Vesselle Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-Small-cell Lung Carcinoma in Relation to Angiogenesis and Proliferation J. Histochem. Cytochem., November 1, 2009; 57(11): 1087 - 1097. [Abstract] [Full Text] [PDF]

				C. V. Dang, A. Le, and P. Gao MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities Clin. Cancer Res., November 1, 2009; 15(21): 6479 - 6483. [Abstract] [Full Text] [PDF]

				T. Harris, G. Eliyahu, L. Frydman, and H. Degani Kinetics of hyperpolarized 13C1-pyruvate transport and metabolism in living human breast cancer cells PNAS, October 27, 2009; 106(43): 18131 - 18136. [Abstract] [Full Text] [PDF]

				C. Yang, J. Sudderth, T. Dang, R. G. Bachoo, J. G. McDonald, and R. J. DeBerardinis Glioblastoma Cells Require Glutamate Dehydrogenase to Survive Impairments of Glucose Metabolism or Akt Signaling Cancer Res., October 15, 2009; 69(20): 7986 - 7993. [Abstract] [Full Text] [PDF]

				J. B. Williams, D. Pang, B. Delgado, M. Kocherginsky, M. Tretiakova, T. Krausz, D. Pan, J. He, M. K. McClintock, and S. D. Conzen A Model of Gene-Environment Interaction Reveals Altered Mammary Gland Gene Expression and Increased Tumor Growth following Social Isolation Cancer Prevention Research, October 1, 2009; 2(10): 850 - 861. [Abstract] [Full Text] [PDF]

				H. C. Champion, E. D. Michelakis, and P. M. Hassoun Comprehensive Invasive and Noninvasive Approach to the Right Ventricle-Pulmonary Circulation Unit: State of the Art and Clinical and Research Implications Circulation, September 15, 2009; 120(11): 992 - 1007. [Full Text] [PDF]

				E. Hulleman, M. J. Broekhuis, R. Pieters, and M. L Den Boer Pyruvate kinase M2 and prednisolone resistance in acute lymphoblastic leukemia Haematologica, September 1, 2009; 94(9): 1322 - 1324. [Full Text] [PDF]

				T. Matsumoto, P.-y. Wang, W. Ma, H. J. Sung, S. Matoba, and P. M. Hwang Polo-like kinases mediate cell survival in mitochondrial dysfunction PNAS, August 25, 2009; 106(34): 14542 - 14546. [Abstract] [Full Text] [PDF]

				B. Perroud, T. Ishimaru, A. D. Borowsky, and R. H. Weiss Grade-dependent Proteomics Characterization of Kidney Cancer Mol. Cell. Proteomics, May 1, 2009; 8(5): 971 - 985. [Abstract] [Full Text] [PDF]

				S MASUNAGA, K TANO, M WATANABE, G KASHINO, M SUZUKI, Y KINASHI, K ONO, and J NAKAMURA Evaluation of the potential of hexamethylenetetramine, compared with tirapazamine, as a combined agent with {gamma}-irradiation and cisplatin treatment in vivo Br. J. Radiol., May 1, 2009; 82(977): 392 - 400. [Abstract] [Full Text] [PDF]

				M. Wu Real-Time Measurement of Mitochondrial Respiration and Glycolysis Rates of Cancer Cells in a Microplate Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 295 - 300. [Full Text] [PDF]

				L. Piao, Y. Li, S. J. Kim, H. S. Byun, S. M. Huang, S.-K. Hwang, K.-J. Yang, K. A. Park, M. Won, J. Hong, et al. Association of LETM1 and MRPL36 Contributes to the Regulation of Mitochondrial ATP Production and Necrotic Cell Death Cancer Res., April 15, 2009; 69(8): 3397 - 3404. [Abstract] [Full Text] [PDF]

				T. Amann, U. Maegdefrau, A. Hartmann, A. Agaimy, J. Marienhagen, T. S. Weiss, O. Stoeltzing, C. Warnecke, J. Scholmerich, P. J. Oefner, et al. GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis Am. J. Pathol., April 1, 2009; 174(4): 1544 - 1552. [Abstract] [Full Text] [PDF]

				E. Hulleman, K. M. Kazemier, A. Holleman, D. J. VanderWeele, C. M. Rudin, M. J. C. Broekhuis, W. E. Evans, R. Pieters, and M. L. Den Boer Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells Blood, February 26, 2009; 113(9): 2014 - 2021. [Abstract] [Full Text] [PDF]

				E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis Clin. Cancer Res., February 15, 2009; 15(4): 1297 - 1307. [Abstract] [Full Text] [PDF]

				L. Liu, D. R. Wise, J. A. Diehl, and M. C. Simon Hypoxic Reactive Oxygen Species Regulate the Integrated Stress Response and Cell Survival J. Biol. Chem., November 7, 2008; 283(45): 31153 - 31162. [Abstract] [Full Text] [PDF]

				F. L. Chen, W. Xia, and N. L. Spector Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors Clin. Cancer Res., November 1, 2008; 14(21): 6730 - 6734. [Abstract] [Full Text] [PDF]

				S. M. Schieke, M. Ma, L. Cao, J. P. McCoy Jr., C. Liu, N. F. Hensel, A. J. Barrett, M. Boehm, and T. Finkel Mitochondrial Metabolism Modulates Differentiation and Teratoma Formation Capacity in Mouse Embryonic Stem Cells J. Biol. Chem., October 17, 2008; 283(42): 28506 - 28512. [Abstract] [Full Text] [PDF]

				M. C. F. Hsieh, D. Das, N. Sambandam, M. Q. Zhang, and Z. Nahle Regulation of the PDK4 Isozyme by the Rb-E2F1 Complex J. Biol. Chem., October 10, 2008; 283(41): 27410 - 27417. [Abstract] [Full Text] [PDF]

				N. J. MacIver, S. R. Jacobs, H. L. Wieman, J. A. Wofford, J. L. Coloff, and J. C. Rathmell Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival J. Leukoc. Biol., October 1, 2008; 84(4): 949 - 957. [Abstract] [Full Text] [PDF]

				K. M. Reilly, J. B. Rubin, R. J. Gilbertson, J. R. Garbow, M. F. Roussel, and D. H. Gutmann Rethinking Brain Tumors: The Fourth Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop Cancer Res., July 15, 2008; 68(14): 5508 - 5511. [Full Text] [PDF]

				R. Ralhan, L. V. DeSouza, A. Matta, S. Chandra Tripathi, S. Ghanny, S. Datta Gupta, S. Bahadur, and K. W. M. Siu Discovery and Verification of Head-and-neck Cancer Biomarkers by Differential Protein Expression Analysis Using iTRAQ Labeling, Multidimensional Liquid Chromatography, and Tandem Mass Spectrometry Mol. Cell. Proteomics, June 1, 2008; 7(6): 1162 - 1173. [Abstract] [Full Text] [PDF]

				H. Shime, M. Yabu, T. Akazawa, K. Kodama, M. Matsumoto, T. Seya, and N. Inoue Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway J. Immunol., June 1, 2008; 180(11): 7175 - 7183. [Abstract] [Full Text] [PDF]

				C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]

				K. C. Rice and K. W. Bayles Molecular Control of Bacterial Death and Lysis Microbiol. Mol. Biol. Rev., March 1, 2008; 72(1): 85 - 109. [Abstract] [Full Text] [PDF]

				N. Shimada, T. Shinagawa, and S. Ishii Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells, March 1, 2008; 13(3): 245 - 254. [Abstract] [Full Text] [PDF]

				M. J. Brauer, C. Huttenhower, E. M. Airoldi, R. Rosenstein, J. C. Matese, D. Gresham, V. M. Boer, O. G. Troyanskaya, and D. Botstein Coordination of Growth Rate, Cell Cycle, Stress Response, and Metabolic Activity in Yeast Mol. Biol. Cell, January 1, 2008; 19(1): 352 - 367. [Abstract] [Full Text] [PDF]

				Z. Zhu, W. Jiang, J. N. McGinley, J. M. Price, B. Gao, and H. J. Thompson Effects of Dietary Energy Restriction on Gene Regulation in Mammary Epithelial Cells Cancer Res., December 15, 2007; 67(24): 12018 - 12025. [Abstract] [Full Text] [PDF]

				J.-w. Kim, P. Gao, Y.-C. Liu, G. L. Semenza, and C. V. Dang Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 Mol. Cell. Biol., November 1, 2007; 27(21): 7381 - 7393. [Abstract] [Full Text] [PDF]

				F. Lopez-Rios, M. Sanchez-Arago, E. Garcia-Garcia, A. D. Ortega, J. R. Berrendero, F. Pozo-Rodriguez, A. Lopez-Encuentra, C. Ballestin, and J. M. Cuezva Loss of the Mitochondrial Bioenergetic Capacity Underlies the Glucose Avidity of Carcinomas Cancer Res., October 1, 2007; 67(19): 9013 - 9017. [Abstract] [Full Text] [PDF]

				E. E.W. Cohen A Disturbance in the Force Mitochondrial Mutations in Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., August 1, 2007; 13(15): 4317 - 4319. [Full Text] [PDF]

				K. Lundholm, U. Korner, L. Gunnebo, P. Sixt-Ammilon, M. Fouladiun, P. Daneryd, and I. Bosaeus Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning Clin. Cancer Res., May 1, 2007; 13(9): 2699 - 2706. [Abstract] [Full Text] [PDF]

				C. V. Dang Role of MYC and HIF in the Warburg Effect and Tumorigenesis Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 69 - 74. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, J.-w. Articles by Dang, C. V. Search for Related Content PubMed PubMed Citation Articles by Kim, J.-w. Articles by Dang, C. V. Related Collections Cellular Pathobiology Cellular Pathobiology: Metabolism and Physiology